<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Introduction</bold> A gentamicin dose, which the physicians select, frequently does not take any pharmacokinetic parameters into consideration.<bold>Aim</bold> To analyse the results of therapeutic drug monitoring (TDM) of gentamicin for those patients who have not had the gentamicin dose adjusted at the beginning of therapy (first group) and for those patients who had the gentamicin dose adjusted at the beginning of therapy (second group).<bold>Methods</bold> We acquired the basic data about patients from the requests for laboratory examination of levels of gentamicin. We measured all the gentamicin concentrations mentioned in this work using the FPIA method.<bold>Results</bold> The monitored set included 379 hospitalized patients during a 4-year period. We divided the monitored set into 2 groups. First group was composed of patients without dose adjustment of gentamicin at the beginning of therapy, and the second group was composed of patients with dose adjustment of gentamicin by the clinical pharmacist at the beginning of therapy. In addition, the patients in each group were divided according to the body mass index (BMI). In the first group of patients, a low percentage of patients had both optimal levels (trough, peak levels). As for patients with BMI > 25 m2/kg, there were only 17 % such cases, and the patients with BMI ≤ 25 m2/kg were only 18.8 %. In the second group, the patients had all trough and peak levels in optimal therapeutic range at obese patients, overweight patients and also at patients with normal weight (p &lt; 0.001).<bold>Conclusion</bold> Adjustment of dosage regimens immediately at the beginning of therapy will provide for administering sufficient doses of antibiotics at the beginning of therapy, which is a pre-condition for a successful anti-infective therapy. Therapeutic monitoring of levels allows for administration of sufficient dose of gentamicin without fear of any undesirable effects.</abstract>

Introduction A gentamicin dose, which the physicians select, frequently does not take any pharmacokinetic parameters into consideration.Aim To analyse the results of therapeutic drug monitoring (TDM) of gentamicin for those patients who have not had the gentamicin dose adjusted at the beginning of therapy (first group) and for those patients who had the gentamicin dose adjusted at the beginning of therapy (second group).Methods We acquired the basic data about patients from the requests for laboratory examination of levels of gentamicin. We measured all the gentamicin concentrations mentioned in this work using the FPIA method.Results The monitored set included 379 hospitalized patients during a 4-year period. We divided the monitored set into 2 groups. First group was composed of patients without dose adjustment of gentamicin at the beginning of therapy, and the second group was composed of patients with dose adjustment of gentamicin by the clinical pharmacist at the beginning of therapy. In addition, the patients in each group were divided according to the body mass index (BMI). In the first group of patients, a low percentage of patients had both optimal levels (trough, peak levels). As for patients with BMI > 25 m2/kg, there were only 17 % such cases, and the patients with BMI ≤ 25 m2/kg were only 18.8 %. In the second group, the patients had all trough and peak levels in optimal therapeutic range at obese patients, overweight patients and also at patients with normal weight (p < 0.001).Conclusion Adjustment of dosage regimens immediately at the beginning of therapy will provide for administering sufficient doses of antibiotics at the beginning of therapy, which is a pre-condition for a successful anti-infective therapy. Therapeutic monitoring of levels allows for administration of sufficient dose of gentamicin without fear of any undesirable effects.

Is gentamicin administered to individual patients in optimal doses already at the beginning of therapy?

Department of Physical Chemistry of Drugs, Faculty of Pharmacy

Department of Pharmacology and Toxicology, Faculty of Pharmacy

European Pharmaceutical Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Introduction A gentamicin dose, which the physicians select, frequently does not take any pharmacokinetic parameters into consideration.Aim To analyse the...

Is gentamicin administered to individual patients in optimal doses already at the beginning of therapy?

Data publikacji: 26 gru 2019

Zakres stron: 11 - 18

Otrzymano: 24 wrz 2018

Przyjęty: 11 sty 2019

DOI: https://doi.org/10.2478/afpuc-2019-0002

Słowa kluczowe
Gentamicin, therapeutic drug monitoring, adjustment of dosage of gentamicin

© 2019 M. Göböová et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Is gentamicin administered to individual patients in optimal doses already at the beginning of therapy?

Data publikacji: 26 gru 2019

Zakres stron: 11 - 18

Otrzymano: 24 wrz 2018

Przyjęty: 11 sty 2019

DOI: https://doi.org/10.2478/afpuc-2019-0002

Słowa kluczoweGentamicin, therapeutic drug monitoring, adjustment of dosage of gentamicin

© 2019 M. Göböová et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
Gentamicin, therapeutic drug monitoring, adjustment of dosage of gentamicin